Clinical Research Directory

Inclusion Criteria * 60 years of age. * AML de novo, except AML 3 and AML 7. * AML with no adverse cytogenetic according to Medical Research Council (MRC) 2010 classification. * Subjects should be eligible for intensive chemotherapy by Daunorubicine, cytarabine, Lomustine. * Eastern Cooperative Oncology Group (ECOG) \< 3 (appendix 1). * SORROR ≤ 3 (appendix 2). * Adequate baseline organ function defined by the criteria below: * Total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN) range except cases clearly not indicative of inadequate liver function * Alanine Aminotransferase (ALAT) and Aspartate Aminotransferase (ASAT) ≤ 3 x ULN * Creatinin ≤ 1.5 x ULN * Adequate cardiac function with Left Ventricular Ejection fraction (LVEF) ≥50% * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. * Women will be menopausal to be enrolled * The patient must give written (personally signed and dated) informed consent before completing any study-related procedure which means assessment or evaluation that would not form part of the normal medical care of the patient and before the start of induction chemotherapy. * Affiliated to the French Social Security (Health Insurance). Exclusion criteria * Subjects with a diagnosis of acute promyelocytic (M3) or megakaryocytic leukemia (M7). * AML with adverse cytogenetic according to the MRC 2010 classification. * AML secondary to Myelodysplastic syndrome (MDS), Myeloproliferative neoplasm (MPN) * Clinical symptoms suggesting active central nervous system leukemia, or presence of extramedullary AML. * Previous exposure to anthracycline. * Previous AML treatment other than hydroxyurea. * Treatment with an investigational drug within 30 days or 5 half-life whichever is longer, preceding the first dose of study medication. * History of thromboembolic event or other condition requiring ongoing use of anticoagulation either with warfarin or low molecular-weight heparin. * History of another malignancy within the past three years except basal cell carcinoma of the skin or carcinoma in situ of the cervix. * Pre-existing cardiovascular disease (including congestive heart failure, New York Heart Association (NYHA) Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a QTc \>450 msec (QTc \>480 msec for subjects with Bundle Branch Block). * Patient requiring platelets transfusion with platelets \> 10 x 10 Giga/L, for whatever reason. * History of treatment with romiplostim or other Thrombopoietin receptor (TPO-R) agonists. * Uncontrolled active infection. * Any serious medical condition, laboratory abnormality, or psychiatric illness that would place the participant at an unacceptable risk or prevent them from giving informed consent. * Known active HIV, Hepatitis B or C infection. * Pregnancy or breastfeeding.